With our clinical science-driven approach, we are pioneering the development of precisely-targeted medicines for cancer patients in need.
Our mission is to develop improved medicines to treat patients with the most difficult-to-treat cancers by furthering the science behind drug development. We are taking a multi-pronged approach to cleverly design oncology medicines with differentiated mechanisms of action to attack and destroy tumors.
We have developed a deep pipeline of investigational agents – both small molecules and antibodies – that have complementary mechanisms of action. They are designed to precisely modulate molecular targets that are well-defined and measurable. This allows us to identify biomarkers to help select the patients who can benefit most.
We extensively test our investigational medicines in preclinical models in order to quickly and efficiently translate this knowledge into science-based clinical trials to determine their optimal clinical utility. We then evaluate these agents in intelligently-designed, rigorously-conducted clinical trials to:
- Assess their safety, tolerability and efficacy in patients with advanced refractory cancers
- Understand how they work at the biological level and confirm their mechanism of action
- Elucidate relevant biomarkers
- Test them as monotherapy, in combination with each other, and in combination with other anti-cancer agents
We study our investigational medicines first in the most seriously ill and difficult-to-treat cancer patients – i.e., those who have failed at least one standard therapy and, in most cases, multiple rounds of treatment. We believe this approach is the most rigorous way to evaluate our medicines. If efficacy for any of our agents is demonstrated in this patient population, we would then explore investigating them as earlier-stage therapies.
We believe in putting patients first. With that in mind, we report our preclinical and clinical data promptly and frequently at major scientific meetings, so our research can be used by others to advance medicine for the benefit of patients.
As our goal is to grow our pipeline, we continue to seek new opportunities both from our own research as well as from outside resources.